2cureX receives first payment of EUR 1,5 million from EU Horizon 2020
2cureX AB (“2cureX”) today announces that the company has received the first payment of an awarded grant comprising EUR 3 million from the EU’s Horizon 2020 SME Program. The grant is given to finalize the clinical validation of the company’s IndiTreat® product and to initiate market launch.As previously communicated (January 2018), 2cureX and the EU agreed on the final terms of a Horizon 2020 SME Instrument grant that in total will provide EUR 3 million (SEK 29 million). The first payment of the grant has now been received by 2cureX. The grant is supporting 2cureX’s clinical validation